Albireo Pharma Competitors, Revenue, Alternatives and Pricing

Claim your profile

Overview

Location:
Boston, MA USA
Total Funding:$40M
Industry:Biotech
Founded:2008
Lead Investor(s):N/A

City Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Albireo Pharma's estimated annual revenue is currently $20.5M per year.(?)
  • Albireo Pharma's estimated revenue per employee is $155,000
  • Albireo Pharma's total funding is $40M.

Employee Data

  • Albireo Pharma has 132 Employees.(?)
  • Albireo Pharma grew their employee count by 48% last year.
  • Albireo Pharma currently has 12 job openings.

Albireo Pharma is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and other liver and gastrointestinal diseases and disorders. Albireo’s lead product candidate, A4250, is directed to treat rare pediatric cholestatic liver diseases and is in Phase 3 development in its initial target indication, progressive familial intrahepatic cholestasis. Albireo’s clinical pipeline also includes two Phase 2 product candidates. Albireo’s elobixibat, approved in Japan for the treatment of chronic constipation, is the first ileal bile acid transporter (IBAT) inhibitor approved anywhere in the world. Albireo was spun out from AstraZeneca in 2008. Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary is located in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com.

keywords:N/A